生命科学资讯
生物技术与制药领域的最新动态
FDA panel votes against J&J's novel shunt implant for heart failure
米歇尔·拉加德出售32,000股赛默飞世尔科技(NYSE:TMO)股票 - MarketBeat
Michel Lagarde Sells 32,000 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock - MarketBeat
RFK Jr.’s hand-picked panel questions childhood vaccine schedule
赛默飞世尔Lagarde出售价值1240万美元股票 - Investing.com
Lagarde of Thermo Fisher sells $12.4m in stock - Investing.com
Thermo Fisher在亚洲的生物工艺三中心扩建会重塑其叙事吗?
Will Thermo Fisher's Asia Bioprocessing Tri-Hub Expansion Reshape Thermo Fisher Scientific's (TMO) Narrative? - simplywall.st
Natera以高达4.5亿美元收购Foresight Diagnostics,加强癌症检测业务。
Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M
编码解密通往关键试验之路:基于1/2期Dravet基因疗法数据
Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data
FDA陷入“前所未有的动荡”威胁公众健康:mRNA联盟发声
'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out
AI与真实世界证据如何驱动药物与设备开发全周期更智能决策
How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle
帕金森病新纪元:Solengepras引领超越多巴胺的治疗转型
A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine
百时美施贵宝扩大Breyanzi适应症至边缘区淋巴瘤。
Bristol Myers expands Breyanzi approval to marginal zone lymphoma
Thermo Fisher Scientific在印度、韩国和新加坡扩大生物工艺能力 - chemengonline.com
Thermo Fisher Scientific expands bioprocessing capabilities in India, Korea and Singapore - chemengonline.com
Other news to note for Dec. 5, 2025
Regulatory actions for Dec. 5, 2025
生物制药筹集的资金
Money raised by biopharma
生物制药融资情况:2025年1月1日至12月4日
Biopharma money raised: Jan. 1-Dec. 4, 2025
BioWorld与纳斯达克股票指数
BioWorld and Nasdaq stock indices
ACIP取消普遍接种乙肝疫苗出生剂次建议
ACIP drops universal hepatitis B birth dose recommendation
英国国家健康与临床优化研究所详述药品涨价支付方案
NICE adds further details on how the UK will pay more for drugs